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Objective: To assess the efficacy of improving diastolic dysfunction with the use of nebivolol, a selective beta-1 
adrenergic receptor antagonist, as compared to spironolactone, a mineralocorticoid receptor antagonist, in the 
treatment of diastolic heart failure. To assess whether or not these medications have a favorable outcome in terms of 
improving exercise capacity in patients with Heart Failure with Preserved Ejection Fraction (HFpEF). Design: 
Systematic Literature Review. Methods: Searches in PubMed and the JMU online library database using mesh terms 
that included “diastolic heart failure”, “nebivolol”, and “spironolactone”. In order to narrow down relevant articles, 
filter terms included “humans”, “published in the last 5 years”, “full text” and “English.”  This literature review 
includes three separate studies pertaining to different treatment modalities for diastolic heart failure. We focused on 
the use of nebivolol as compared to spironolactone as mainstay therapies in the treatment regimen for heart failure 
with a preserved ejection fraction. The Aldo-DHF randomized control trial was included for its research in assessing 
the efficacy of improving diastolic function and maximizing exercise capacity in patients with HFpEF. The study 
with a focus on treatment with spironolactone in elderly women with HFpEF was included because it focused on 
baseline and endpoint data concerning improvement in exercise capacity as well as left ventricular (LV) structure 
and function on echocardiogram and biomarkers such as brain natriuretic peptide (BNP). The ELANDD study was 
included because it discussed mechanisms of nitric oxide release and subsequent peripheral vasodilation, which was 
hypothesized to improve aortic and ventricular compliance and thus improve diastolic filling. Results – 
spironolactone was found to improve left ventricular diastolic function, but had no effect on maximal exercise 
capacity and did not improve patient symptoms or quality of life. Spironolactone was also shown to have beneficial 
effects on the remodeling of the ventricle. The selective beta-1 adrenergic receptor antagonist, nebivolol, was found 
to have no improvement in maximal exercise capacity and was found to have a neutral effect on both peak oxygen 
uptake during exercise and pro brain natriuretic peptide plasma levels (pro-BNP). Nebivolol did decrease resting and 




Heart failure is characterized by an inability to produce a cardiac output sufficient enough to perfuse and 
oxygenate vital organs and tissues while maintaining adequate and normal filling pressures in the heart. It is broken 
down into two distinct phenotypes, including systolic failure (reduced ejection fraction) and diastolic failure 
(preserved ejection fraction).  
 
Systolic heart failure is characterized by impaired contractility of the myocardium, which allows for normal 
diastolic filling but results in a reduced volume of blood ejected from the ventricle. This combination of normal 
filling with reduced ejection results in increased end systolic volumes and thus volume overload in the ventricle. 
Systolic failure is typically associated with dilation of the left ventricle (LV), or eccentric remodeling, as a result of 
volume overload. This type of failure is typically defined by an ejection fraction (EF) < 45%. [3] 
 
Diastolic heart failure is characterized by stiffened ventricles, which result in an inability of the ventricles 
to relax and amounts to poor diastolic filling and a reduced end diastolic volume (EDV). The preservation of the 
ejection fraction in diastolic failure is a result of initially low EDV with a normal contractile force during systole, 
which allows for full emptying of the ventricle upon contraction. Diastolic failure is typically associated with 
hypertrophy of the left ventricle as a result of concentric remodeling due to pressure overload. This type of failure is 
typically defined by an ejection fraction of >45 %. [1] 
 
 The distinction between systolic and diastolic heart failure is important, as each is phenotypically different 
from the other and thus have differing etiologies and treatment modalities. It is also important to note the difference 
between diastolic “dysfunction” and “failure”. Dysfunction describes the mechanical properties, referring only to 
abnormal relaxation or filling, regardless of EF. Diastolic “failure” refers to diastolic dysfunction in the presence of 
a preserved EF and clinical symptoms of heart failure. [1] 
 In diastolic failure, inadequate relaxation of the LV in addition to loss of ventricular wall compliance 
results in poor filling, a low stroke volume, and a pressure increase in the left atrium as well as the pulmonary veins. 
This increase in LV pressure ultimately causes increased pulmonary pressures and manifests clinically as dyspnea 
and limitations in exercise as a result of pulmonary congestion and fluid overload. [1] 
 The etiology among patients with heart failure with preserved ejection fraction (HFpEF) is different from 
those patients with a reduced ejection fraction. Notably, chronic systemic hypertension is one of the most common 
causative factors in patients with HFpEF, with obesity as another significant causative factor. Etiologies that 
commonly result in ischemic conditions cause poor oxygenation of myocytes, an inability to make sufficient 
amounts of ATP for the process of calcium removal by the sarcoplasmic reticulum (SR) and thus poor relaxation of 
the myocardium. LV chamber stiffness and increased resistance to filling results in increased LV filling pressures 
and higher pressures in the lung capillary beds. See Table 1 to distinguish etiologies, pathophysiology, and signs and 
symptoms of systolic and diastolic heart failure. [1][8] 
 
Table 1. Comparison between Systolic and Diastolic Heart Failure  
 
  
Heart Failure with Reduced Ejection Fraction  
“Systolic Heart Failure” 
 
Heart Failure with Preserved Ejection Fraction  







• Coronary artery disease 
• Diabetes mellitus 
• Hypertension 
• Valvular heart disease  
• Arrhythmia (SVT or ventricular) 
• Ischemic cardiomyopathy 
• Dilated cardiomyopathy  
• Congenital heart disease 
• Drugs and alcohol  
• Idiopathic  
 
 
• Coronary artery disease 
• Diabetes mellitus 
• Hypertension 
• Valvular heart disease  
• Hypertrophic cardiomyopathy 
• Restrictive cardiomyopathy  








• Normal relaxation/filling  
• Poor contractility, impaired emptying 
• Normal EDV with increased ESV 
• Increased diastolic pressure  
• Ventricular dilation  
• EF < 45% 
 
• Impaired relaxation - Loss of LV wall 
compliance   
• Low EDV 
• Increased end diastolic pressure  
• LV Hypertrophy  
• EF > 45% 





• Dyspnea, Cough 
• Orthopnea and paroxysmal nocturnal dyspnea  
• Peripheral edema (ankle swelling)  
• Fatigue and weakness  






• Pulmonary congestion (edema, crackles) 
• Elevated jugular venous pressure 
• Hepatosplenomegaly, ascites  
• Displaced PMI  
• Renal hypoperfusion  
• Rapid/irregular heart rate 
Table 1 depicts basic similarities and differences between systolic and diastolic heart failure. Common etiologies and 
pathophysiology behind each type of heart failure often differ significantly, while signs and symptoms associated with heart 
failure in general are often similar, regardless of ejection fraction. [1][8] 
 
The diagnosis of HFpEF may be made based on a clinical picture consistent with diastolic failure, an EF > 
45%, and evidence of LV dysfunction on echocardiogram. On physical exam, pulmonary congestion manifested as 
adventitious lung sounds (crackles, rales, rhonchi) and jugular venous distention may be present. An 
echocardiogram may reveal abnormal LV filling and left atrial enlargement. Cardiac catheterization may reveal 
elevations in filling (diastolic) pressures either at rest or during exercise and strenuous activity. The NYHA 
functional classification system is used to assess both the severity and limitations of heart failure patients. It refers to 
heart failure in general, regardless of ejection fraction. This system is explained in Table 2. [2] 
 





























Symptoms of heart failure at rest or with very little exertion 
Table 2 refers to the New York Heart Association (NYHA) functional classification system. It is the most commonly 
used system to classify heart failure patients based on the severity of their symptoms. Patients are placed in one of 
four categories based on their level of limitation and symptom onset during exercise. [2] 
 In terms of treating diastolic heart failure, concrete treatment regimens have not yet been established like 
they have been for systolic heart failure. As the physiology behind diastolic failure differs substantially from that of 
systolic failure, the pharmacologic treatments that are effective in patients with a reduced EF are not necessarily 
successful in patients with a preserved EF. Due to the lack of a proven regiment, treatment at this time is directed 
towards contributing factors and comorbidities including hypertension and coronary artery disease, in addition to 
symptom relief with diuretics. [1] 
Clinical Scenario  
Ms. AC is a 72-year-old Caucasian female with a body mass index (BMI) of 28.5 who presents today with 
signs and symptoms consistent with heart failure. Ms. AC has been short of breath for the past 72 hours and her 
dyspnea is worse with exertion, while lying flat, and at night, but gets a little better when she sits up-right and rests. 
Ms. AC complains of constant fatigue that has been worse in the last two days and reports that her legs and ankles 
have been “puffier than normal” this past week. Ms. AC reports no recent illness, but states she has had a cough for 
months and just always feels a little run-down, especially when she cleans the house or walks up even a few stairs. 
Ms. AC reports no chest pain or discomfort today, but states that her heart “feels a little fast” and she’s anxious this 
morning because she’s worried about her health. Ms. AC is a 20-pack-year smoker and her diet is high in fat and 
sugary beverages, but she reports cutting down significantly in the past 2 months. 
Ms. AC’s past medical history is significant for type 2 diabetes mellitus for 20 years, hypertension for 20 
years, osteoporosis for 10 years, and dyslipidemia for 10 years, which are all well controlled with 2g of metformin 
BID and 16 units of lantus with breakfast, 40 mg of lisinopril BID, 5 mg of alendronate QD, and 40 mg atorvastatin 
QD.  
Clinical Question  
 
In adults with HFpEF (LVEF >45%) who are 40 years of age or older, does spironolactone as compared to 
a selective B1 beta blocker (nebivolol) improve exercise capacity and reduce diastolic dysfunction, therefore 





An initial investigation for research articles was performed in September 2016 using the PubMed search 
engine and the James Madison University online library database. Search terms included “heart failure with 
preserved ejection fraction”, “spironolactone”, “nebivolol”, “diastolic heart failure”, “beta blockers”, and 
“mineralocorticoid receptor antagonists.” These terms produced 482 results and after duplicates were removed, 375 
articles remained. Excluding articles that were not in full text, not in English, not using human subjects, and articles 
that were published more than 5 years ago allowed us to further narrow our search. The remaining 180 articles were 
assessed for eligibility. Of these articles, 89 were excluded if the population study included participants less than 40 
years of age, if left ventricular ejection fraction was less than 45%, and if the studies were looking at populations 
with less than class II heart failure, based on the New York Heart Association (NYHA) classification. Meta-analyses 
research articles were also excluded, leaving 91 articles for qualitative synthesis. See Table 3 for study criteria.  
 
 






Exclusion Criteria  
 
• Cohort 
• Randomized Control Trial 
• English 
• Humans  
• Class II or III Heart Failure  
• Full-text  
• Evidence of diastolic failure on 
echocardiogram  




• Studies older than 5 years  
• Non-human populations  
• Class I Heart Failure  
• Less than 40 years of age  
• LVEF < 45% 
• Meta-analysis  
 
 
 The qualitative synthesis was then further narrowed to the final 3 articles. This was done so using the 
specific inclusion criteria of patient population of greater than or equal to 40 years of age, left ventricular ejection 
fraction of greater than 45%, and a diagnosis of heart failure with preserved ejection fraction in NYHA function 
class II-III. We also consider the year each article was published, sample size, and the journal from which our 
articles were published. See Table 4 below for details on quality assessment.  
 
Articles with double-blinded randomized control trials and monitoring of diastolic dysfunction with an 
echocardiogram were also included in our analysis. In addition to the echocardiogram, we included articles that used 
a 6-minute walk distance test and measured peak VO2. Since there are no studies to date directly comparing 
nebivolol and spironolactone, we used studies comparing each medication against a placebo. The process of article 
selection is detailed in appendix 1. See Table 4 for details on the quality assessment for each article included in this 



































Journal of the American Medical 
Association  
 
Journal of Cardiac Failure Vol. 20 
No. 8 
 
European Journal of Heart 
Failure  
 







Table 5. Overview of Studies Included in Literature Review 
 Study #1: Spironolactone vs 
Placebo 
Study #2: Spironolactone vs 
Placebo 
Study #3: Nebivolol vs 
Placebo 
Study Design Double-blind, Randomized, Placebo-controlled 
Duration of 
Study 
12 months 6 months 6 months 
Efficacy 
Outcomes 
6-Minute Walking Distance 
E/e’ Velocity Ratio 
E/A Velocity Ratio 
Peak VO2 Levels 
NT-proBNP Levels 
6-Minute Walking Distance 
E/e’ Velocity Ratio 
E/A Velocity Ratio 
BNP Levels 
PIIINP Levels 
6-Minute Walking Distance 




Spironolactone (25 mg QD) 
n = 213 
Placebo (25 mg QD) 
n = 209 
Spironolactone (25 mg QD) 
n = 24 
Placebo (25 mg QD) 
n = 24 
Nebivolol (2.5 mg QD) 
n = 57 
Placebo (2.5 mg QD) 
n = 59 
Table 5 depicts an overview of each article included in this literature review including the type of study design and 
duration of each study, as well as primary and secondary outcomes for each study. This table also provides a 
breakdown of participants between study and control groups, as well as medications and the dose used. [4][5][6] 
 
E wave = early diastolic filling; A wave = late diastolic filling. Both refer to mitral inflow. Normally the E wave 
should be taller than the A wave, as more filling occurs passively (E) than during the atrial kick (A) at the end of 
diastole. The E/e’ ratio is derived by dividing the max flow velocity of the mitral valve inflow (early filling) by the 
max velocity of E.VO2 refers to the maximal oxygen consumption or use during exercise. NT-pro BNP, or BNP, 
refers to the brain natriuretic peptide which is secreted from the ventricles in response to over stretching. When 





Effect of Spironolactone on Diastolic Function and Exercise Capacity in patients with Heart Failure with Preserved 




The objective of the study was evaluating the use of spironolactone as compared to placebo in the treatment 
of heart failure with preserved ejection fraction. The primary outcomes that were investigated include the effects on 
diastolic function and exercise capacity while assessing the long term efficacy and safety of mineralocorticoid 
receptor antagonists.  
 
Study 1 Design  
 
This was a randomized controlled double-blinded study with 422 patients from ten different sites in 
Germany and Austria. All 422 patients were randomized using the Pocock’s minimization algorithm on a 1:1 basis 
to receive spironolactone (n = 213) or placebo (n = 209).  
 
Patients in the spironolactone group received 25 mg/day for a total of 12 months in duration. The primary 
endpoints in this study included change in maximum exercise capacity (Peak VO2 on spiroergometry) and the E/e’ 
ratio (ratio of peak early transmitral ventricular filling velocity to early diastolic tissue Doppler velocity) measured 
on an echocardiogram at 12 months and compared to baseline. The exercise test and echocardiogram were 
performed twice, once at screening and once at baseline, to ensure reproducibility. All echocardiogram data were 
reviewed by a blinded lab tech that was trained by two national echocardiogram coordinators acting as blinded 
reference centers. An echocardiogram operating procedure was constructed to provide standard parameters for the 
data. Diastolic function was classified into four grades based on E/e’ ratio and E/A ratio, or the ratio between early 
diastolic filling and late diastolic filling (or the atrial kick). See Table 6 for grading classifications based on 
echocardiogram measurements (E/e’ and E/A ratios, specifically). [5][7] 
 
Table 6. Classification of Diastolic Function in the Aldo-DHF study (Study 1 – 





– Grade I 









          ≥ 1          < 1       ≥ 1 and < 2        ≥ 2         ≥ 2 
E/e’ 
Ratio 
         < 10     Not graded             ≥ 10       ≥ 10        ≥ 10 
 
Table 6 depicts the classification of diastolic function based on the E/A and E/e’ ratios obtained from 
echocardiography. E wave = early diastolic filling; A wave = late diastolic filling. Both refer to mitral inflow; that 
is, filling of the left ventricle via the mitral valve. The E/e’ ratio is derived by dividing the max flow velocity of the 
mitral valve inflow (early filling) by the max velocity of E. Study 1 defines a normal E/e’ ratio of <10. The ratio will 
increase if there is diastolic dysfunction, which results in an E-wave that increases with higher filling pressures. 
Under normal conditions (no diastolic dysfunction), the filling of the left ventricle is passive. The E wave (early 
filling) is taller than the A wave (later filling). In the presence of diastolic dysfunction, the ventricle becomes stiff, 
cannot relax properly during diastole, and thus impairs early filling, resulting in a decreased magnitude of the E 
wave. As less blood fills the ventricle during passive filling (early diastole), more blood is left in the atrium. When 
late filling occurs, more blood is ejected from the atrium and thus an increase in the magnitude of the A wave 
occurs. This results in an E/A ratio of <1 (delayed relaxation, grade I). [5][7] 
 
Similarly to the echocardiogram operations, the spiroergometry testing also used a blinded reference lab to 
train investigators on the procedures of the instrumentation and evaluation of any related cardiopulmonary exercise 
testing. The exercise testing consisted of bicycle ergometer starting with a workload of 20 watts and increasing 20 
watts in 2-minute intervals. An ECG was used to record continuous heart rate, monitor for arrhythmias, and observe 
for and ST-segment changes. Blood pressure was measured at baseline and every 2 minutes thereafter. Ventilatory 
exchange (peak VO2) was calculated by averaging breath-by breath measurements over 10 second intervals. The 
peak VO2 is defined as the maximum value of the last three 10 second averages during exercise. Blood samples of 
N-terminal pro-brain-type natriuretic peptide (NT-proBNP), sodium, potassium, hemoglobin, and estimated 
glomerular filtration rate (eGFR) were collected after 20 minutes of lying in the supine position following the 
cardiopulmonary exercise test.  
 
Office visits for the study included the screening visit, baseline visit, follow up after one week, and 
continued follow up at 3, 6, 9, and 12 months. At 6 and 12 month follow up visits, an echocardiogram, 
cardiopulmonary exercise test, 6-minute walking test, and blood sample were obtained. See Table 7 for inclusion 












• Males and females age ≥ 50 years of age  
• NYHA class II or III 
• LVEF > 45% 
• Echocardiographic evidence of diastolic 
dysfunction of grade ≥ 1 OR atrial 
fibrillation at presentation  
• Peak VO2 of ≤ 25 mL/kg/min  
 
 
• Prior documented reduced LVEF <45% 
• Significant coronary artery disease (CAD) 
• Myocardial infarction OR coronary artery bypass surgery ≤ 3 
months prior to enrollment  
• Relevant pulmonary disease (Vital capacity < 80% or FEV1 < 
80% predicted)  
• Significant Lab Abnormalities  
• Known contraindications or known intolerance to therapy 
with MRA’s in last 3 months.  
• Concomitant therapy with potassium-sparing diuretic 
(Triamterene, Amiloride) 
• Potassium supplementation  
 
Significant Lab Abnormalities - (K+ ≥ 5.1 mmol/L; Hgb ≤ 11 g/dL; Hct ≤ 33%; Serum creatinine > 1.8 mg/dL; 
Estimated GFR < 30 mL/min/1.73 m2) Significant CAD - current angina pectoris or ischemia on stress test, or 
untreated coronary stenosis > 50% MRA – mineralcorticoid receptor antagonists (like spironolactone) 
 




Of the 422 patients that underwent the study, the mean average age of the patient population was 67 and of 
those 422 patients, 52% were women. Characteristics of the patients’ medical histories included 92% of the patients 
having a current history of hypertension, 65% with hyperlipidemia, 40% with coronary artery disease, 17% diabetes 
mellitus, 3% chronic obstructive pulmonary disease, and 5% with a history of atrial fibrillation. On average, the total 
BMI for the study was 28.9; indicating most of the patients were overweight or obese. The study included NYHA 






Results from the study indicated that diastolic function was improved with the use of spironolactone as 
compared to placebo. Measurements from the echocardiogram proved so with a decrease in the E/e’ from 12.7 at 
baseline to 12.1 after 6 months. On the other hand, patients taking placebo had an increase in E/e’, starting at 12.8 at 
baseline and then increasing to 13.6 after 12 months. These results carried a P value of < .001, suggesting statistical 
significance.  
 
E/A velocity ratio on echocardiogram was 0.90 for spironolactone and 0.92 for the placebo group at 
baseline. After 12 months of treatment the spironolactone group E/A velocity ratio increased to 0.91 and the placebo 
group increased to 0.96. The P value was .08, indicating no true statistical significance, however, improvement in 
the E/A ratio with the use of spironolactone may be significant with a study that is longer in duration because there 
would be more time for structural changes of the heart. See Figures 1 and 2 at the end of this section for E/e’ and 
E/A ratio measurements, respectively.  
 
A co-primary endpoint was the peak VO2. Patients taking spironolactone improved from baseline scores, 
increasing from 16.3 mL/min/kg to 16.8 mL/min/kg. Patients taking placebo also increased their Peak VO2 from 16.4 
mL/min/kg to 16.9 mL/min/kg. These measurements suggest no significant difference between study and control 
groups, with a P value of 0.81. See Figure 3 for peak VO2 measurements in both the study and control groups.  
 
Secondary endpoints included a decrease in left ventricular mass index (LVMI), as seen on the 
echocardiogram, and a decrease in the levels of NT-proBNP. At baseline, LVMI of patients on spironolactone were 
108 g/m2, eventually decreasing to 100 g/m2 after 12 months of treatment. The LVMI for patients in the placebo 
group were 109 g/m2 at baseline and decreased to 106 g/m2 after 12 months.  Similarly, patients taking showed a 
decrease in NT-proBNP, from 2.22 ng/L to 2.18 ng/L, whereas patients on placebo had increased levels from 2.19 
ng/L to 2.22 ng/L after 12 months. The P values for LVMI and NT-proBNP were 0.16 and 0.8, respectively. This 
suggests that, while there was a difference between the use of spironolactone vs placebo, neither the decrease in pro-
BNP levels or LVMI were statistically significant.  Patients taking spironolactone, as compared to placebo, did see a 
reduction in systolic blood pressure after 12 months. There was a slight decrease in the 6-minute walking distance 
for patients in the spironolactone study group. Neither finding was statistically significant. See Figures 4 and 5 for 
NT-proBNP levels and 6-minute walking distances, respectively.  
 
In patients assigned to the spironolactone study group, there was a mild increase in potassium levels at 1 
week, which remained stable throughout the duration of the study. A significant number of patients in the 
spironolactone group (13 as compared to 7 in the placebo group) had potassium levels  >5.5 mmol/L. This finding 
was expected, as spironolactone is a potassium sparing diuretic and increased serum potassium levels are common in 
patients taking this medication. However, the group taking placebo also saw an increase in serum potassium in 7 
patients, which, while not due to use of a potassium sparing diuretic, could be due to the concomitant use of ACE 


























Time	  Since	  Randomization	  
Figure	  1.	  E/é	  Velocity	  Ratio	  




















Time	  Since	  Randomization	  
Figure	  2.	  E/A	  Velocity	  Ratio	  	  


















Time	  Since	  Randomization	  
Figure	  3.	  Peak	  VO2	  	  	  

















Time	  Since	  Randomization	  
Figure	  4.	  NT-­‐proBNP	  ng/L	  
	  
Spironolactone	   Placebo	  
Figure 2 – Edelmann et al (Study 1) – E/A ratio  
Figure 3 – Edelmann et al (Study 1) – Peak VO2   Figure 4 – Edelmann et al (Study 1) – NT-proBNP   
Figure 1 – Edelmann et al (Study 1) – E/e’ ratio 
 
 




Study 1 Critique  
 
 This study was a double blind, randomized control trial that included 422 participants from 10 different 
sites in Germany and Austria. The patient population was much larger than comparative studies and it is diverse in 
its participant pool. However, considering the local population in Harrisonburg, VA, or even surrounding areas in 
Virginia and the rest of the United States, the populations may vary tremendously. While the study is diverse, 
including 10 different countries, it may not be as applicable locally. The mean age was 67 with 52% of participants 
being female, which is representative of the general population with HFpEF. All participants had similar baseline 
characteristics including a designation by the NYHA of class II or III heart failure and a preserved ejection fractions 
of ≥ 45%. While all patients did present with similar baseline findings, this study did allow for the inclusion of 
patients with either evidence on echocardiogram of diastolic dysfunction or atrial fibrillation at presentation. This 
inclusion criterion is acceptable, as atrial fibrillation can cause a rapid ventricular response, which results in a 
reduction of left ventricular filling during diastole and thus poor cardiac output. However, patients with atrial 
fibrillation may or may not go on to develop true diastolic dysfunction in the long term in the event that a patient 
spontaneously converts to normal sinus rhythm and thus no longer meets inclusion criteria for diastolic heart 
“failure.”   
 
 This study chose to focus equally on co-primary endpoints including changes in diastolic function, based 
on E/e’ values, as well as maximal exercise capacity, based on peak VO2 and a 6 minute walking distance. This co-
ranking of end points allowed for maximal focus to be put on both exercise capacity and structural changes in the 
heart, where as other studies may only focus on one or the other.  
 
 The exclusion criteria is also significant, deeming participants not eligible in the case of significant CAD, 
MI or CABG surgery in 3 months prior to enrollment, significant lung disease based on FEV1 values of <80%, in 
addition to elevated potassium and serum creatinine, low GFR, and hematocrit < 33%. These exclusion criteria, 
while probably necessary in order to ensure the safety of study participants, does exclude a large majority of heart 
failure patients, many of whom have multiple comorbidities, especially those involving the renal and 
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Figure 5 – Edelmann et al (Study 1) – six-minute 
walking distance    
Study 2. 





To explore the effects of spironolactone in elderly women as compared to placebo in combination with 
patients who chronically taking angiotensin-converting-enzyme inhibitors (ACEI) or angiotensin II receptor 
blockers (ARB) therapy for heart failure with preserved ejection fraction. The study examined short-term primary 
outcomes of diastolic function. 
 
Study 2 Design  
 
This was a randomized, placebo controlled trial with 48 female patients from the Methodist Hospital in 
Houston Texas. Randomization of 48 patients took place on a 1:1 to basis to receive spironolactone (n=24) or 
placebo (n=24). The patients in the spironolactone group received 25 mg/day for a total of 6 months in duration.   
 
Throughout the study, serum electrolytes including potassium, sodium, chloride, and bicarbonate, as well as blood 
urea nitrogen (BUN) and serum creatinine, were monitored. Monitoring took place at weeks 2, 6, 13, 25, and 27. 
The study measured a 6-minute walking distance, performed an echocardiogram, measured serum biomarkers levels, 
and administered the Kansas City Cardiomyopathy Questionnaire clinical summary score (KCCQ score), interpreted 
at 3 and 6 months to evaluate the effects of spironolactone on exercise tolerance, functional capacity, symptoms, and 
echocardiographic doppler measurements. The Doppler echocardiogram was a two-dimensional study and was 
performed by an experienced echocardiographer who was blinded to the study. The evaluation of biomarkers 
included troponin and brain natriuretic peptide (BNP). A commercial lab, that was also blinded, collected these 
measurements. Since the patients were previously on an angiotensin-converting-enzyme inhibitor (ACE-I) in 
addition to the study drug, spironolactone, serum potassium was monitored for the duration of the study, at weeks 2, 
6, 13, and 25. Inclusion and exclusion criteria are outlined in Table 8 below. [6] 
 
 








• Age ≥ 18 years of age  
• NYHA class II or III  
• LVEF > 45% 
• Diastolic dysfunction with elevated left ventricular 
filling pressure (E’ < 10 cm/s and lateral E/e’ >15)  
• BNP > 62 pg/mL 
• BP ≤ 150/95 mmHg for 4 weeks prior to enrollment  
• Ability to walk ≥ 50 meters at time of enrollment 
• Treatment with ACEI or ARB for at least ≥ 4 weeks 
(prior to enrolling)  
 
• Current treatment with Spironolactone or Eplerenone  
• Previous intolerance to Spironolactone  
• SCr > 2.5 mg/dL 
• Serum K+ > 5.0 mEq/L 
• Significant valvular heart disease  
• Pericardial disease  
• Severe chronic lung disease w/ cor pulmonale  
• Unstable angina OR MI ≤ 4 weeks prior to enrollment  
• Severe PVD w/ claudication that limits walking distance  
• Severe comorbidities with life expectancy < 6 months 
duration  
• Pregnant  
• Lactating female  
NYHA = New York Heart Association (classification of heart failure); LVEF = Left Ventricular Ejection Fraction; 
ACEI = angiotensin-converting-enzyme inhibitor; ARB = Angiotensin II receptor blockers; PVD = peripheral 
vascular disease; MI = Myocardial Infarction; BP = blood pressure; SCr = serum creatinine; K+ = Potassium [6] 




This study had a sample size of 48, with the average age being 70 and with 100% of the patients being 
female. Baseline health status included 83% of the patients with a history of chronic hypertension, 35% with 
coronary artery disease, 37.5% with diabetes mellitus, and 25% with atrial fibrillation. Patients in the NYHA 
functional classes II and III were included in the study, with 42% of the patient population falling into class II and 
58% into class III. The average BMI for patients in this study was 27.85, which classifies most patients as 
“overweight” based on BMI alone.  All of the patients were also previously taking either an ACEI or ARB, with one 




Results from echocardiogram measurements showed a benefit from taking spironolactone as compared to 
the placebo. The lateral E/e’ ratio decreased from 16.5 ± 1.2 at baseline to 14.0 ± 0.8 at 6 months for patients taking 
spironolactone and remained essentially the same, with values of 12.5 ± 0.5 at baseline and 12.0 ± 0.5 after 6 
months. These results produced a P value of 0.0001, which suggests statistical significance.  
 
The mitral E/A ratios at baseline produced values of 1.5 ± 0.1 and 1.6 ± 0.1 for patients in the 
spironolactone and placebo groups, respectively. After six months of treatment, E/A ratios of 1.6 ± 0.1 and 1.9 ± 0.2 
were produced for patients in the spironolactone and placebo groups, respectively. Mitral E/A ratio had a significant 
change overall in both treatment groups with a P value of < 0.05, which is statistically significant. See figures 6 and 
7 for results of E/e’ and E/A ratios, respectively.  
 
The six-minute walking distance test was significantly improved in both treatment groups. The patients 
taking spironolactone walked 250 meters ± 20 at baseline and improved to 272 meters ± 22 after 6 months of 
treatment. The placebo group walked 228 meters ± 12 at baseline and improved to 256 meters ± 13 after 6 months. 
Both were significant (P <0.05). See figure 8 for 6-minute walking distance measurements.  
 
At baseline, serum BNP was measured at 215.4-pg/mL ± 19.0 and 139.4 pg/mL ± 10.6 for the placebo and 
spironolactone groups, respectively. The significantly higher baseline BNP levels in the placebo group were likely 
due to the age difference in the two groups. After 6 months of treatment, BNP levels decreased, measuring 166.9 
pg/mL ± 13.3 and 119 pg/mL ± 10.9 for the placebo and spironolactone groups, respectively.  After adjusting for 
age, the statistics favored spironolactone as compared to placebo, but did not reach statistical significance, with a P 
value of 0.074. See figure 9 for BNP measurement comparisons.  
 
Measurements for type III procollagen (PIIINP) were also measured and decreased from 5.6-µg/L ± 0.4 at 
baseline to 5.1-µg/L ± 0.4 at 6 months in patients taking spironolactone. Levels in the placebo group increased from 
5.6-µg/L ± 0.3 at baseline to 6.6-µg/L ± 0.4 after 6 months. These changes were significant (P = 0.035) and indicate 
that treatment with spironolactone may decrease myocardial fibrosis by significantly reducing the synthesis of type 
III procollagen. There was no difference between the study groups for systolic or diastolic blood pressures over the 
duration of the study. See figure 10 for type III procollagen measurements.  
 
Three participants in the spironolactone treatment group had to withdrawal from the study due to 
hospitalization for hyperkalemia (serum potassium ≥ 6.0 mEq/L). Transient hyperkalemia (≥ 5.5 mEq/L but < 6.0 
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Figure 6 – Kurrelmeyer et al (Study 2) – E/e’ ratio Figure 7 – Kurrelmeyer et al (Study 2) – E/A ratio 
Figure 8 – Kurrelmeyer et al (Study 2) – six-minute 
walking distance 




   
 
 
Study 2 Critique  
 
 This study was a double blind, randomized control trial, which allowed for blinding of both the study group 
and the researchers in order to eliminate bias. All participants had similar baseline characteristics in terms of a 
previous diagnosis of heart failure with ejection fraction ≥ 45% and all were considered to be heart failure class II or 
III by the New York Heart Association (NYHA) classification system.  
 
 While this study adequately randomized and blinded all allocation of study drug vs placebo, the number of 
study participants was low, at 48, all of whom were female. This is not uncommon, as a majority of heart failure 
patients with preserved ejection fraction are women, however, study results may not apply to the general population 
of both males and females. All participants were also from the same hospital in Houston, TX, accounting for 
minimal variability in terms of patient demographics.  
 
This study conducted a 4 week “open label” phase, in which baseline serum creatinine and potassium were 
followed to ensure levels were below 2.5 mg/dL and 5.0 mEq/L, respectively. Serum potassium was also checked 
consistently at weeks 2, 6, 13, 25, and 27 to ensure no hyperkalemia develops, in which case the patient would not 
continue with the drug treatment. Safety measures taken to ensure control of serum potassium were extensive, but 
necessary, as this medication is known to increase serum potassium levels, which can be fatal if ignored. 
 
 The exclusion criteria for this study were extensive, excluding patients with valvular disease, pericardial 
disease, COPD, cor pulmonale, and unstable angina. This is problematic, considering the multitude of comorbidities 
this particular population may suffer from, in addition to heart failure. The results of this study may in fact be 
skewed towards a particular population of heart failure patients in which no other cardiac comorbidities exist, which 
is not necessarily the norm.   
 
Patients were also screened for intolerance to the use of an ACEI or ARB and then treated with these 
medications during the 4-week open label phase. Patients were also required to have a blood pressure of ≤ 150/95 
mmHg for 4 weeks prior to the start of enrollment. This extensive screening process and pre-treatment regimen 
required during the open-label phase of this clinical trial effectively removes potentially eligible candidates from 
enrollment in order to study only a specific subset of heart failure patients, therefore does not accurately represent 


















Time	  Since	  Randomization	  
Figure	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Figure 10 – Kurrelmeyer et al (Study 2) – type III 
procollagen (PIIINP) 
Another limitation of this study includes age difference between spironolactone and placebo groups. Even 
with randomization, the small sample size allowed for possible allocation bias. This age difference may account for 
differences in primary and secondary endpoints including the 6 minute walking distance, ECHO measurements, and 





Study 3.  
Effects of the Long-Term Administration of Nebivolol on the Clinical Symptoms, Exercise capacity, and Left 




To assess the effects of nebivolol as compared to placebo on exercise capacity in patients with heart failure 
with preserved ejection fraction. Diastolic function and exercise tolerance were the primary outcomes analyzed. 
 
Study 3 Design  
 
This was a randomized controlled, double-blinded, parallel group study design with a total of 116 patients. 
All 116 patients were randomized on a 1:1 basis to receive nebivolol (n = 57) or placebo (n = 59). Patients in the 
nebivolol group received 2.5 mg/day and were gradually titrated up to 10 mg/day over a 5-week period. Treatment 
was administered for a total duration of 6 months, or 21 weeks in addition to the 5-week titration period. The 
primary endpoint that was evaluated in this study was the 6-minute walking test (6MWT), which was measured at 
baseline and at 6 months. Secondary endpoints include patient symptoms, exercise capacity assessing peak  VO2 and 
parameters of left ventricular function. The Conraads et al study also observed major outcomes such as mortality, 
hospitalizations, and unexpected visits to the heart failure clinic as well as other adverse events. Inclusion and 












• Willing and able to sign informed consent  
• Age ≥ 40 years  
• Documented history of heart failure 
• Persistent symptoms during effort 
• NYHA class II or III 
• LVEF > 45% 
• LV end diastolic internal diameter < 3.2 cm/m2 OR LV 
end diastolic volume index < 102 mL/m2  
• Any LV diastolic dysfunction (documented by ECHO) 
• E/E’ > 15 (on tissue doppler ECHO)  
• E/E’ ratio of 8 to 15 with other diastolic dysfunction  
 
 
• Acute coronary or cerebrovascular ischemic 
event in 3 months prior to enrollment  
• Exercise-induced myocardial ischemia in 3 
months prior to enrollment  
• Contraindications to beta blocker treatment  
• Ongoing treatment with beta blocker therapy, 
verapamil, diltiazem  
NYHA = New York Heart Association (classification of heart failure); LVEF = Left Ventricular Ejection Fraction; 
LV = left ventricular; ECHO = echocardiogram; ms = milliseconds “Other Diastolic Dysfunction” = E/A < 0.5 
and/or deceleration half-time > 280 ms in patients > 50 years of age and/or duration of reverse pulmonary vein 
atrial systole flow – mitral valve atrial wave flow > 30 ms, and/or left atrial volume index >40 mL/m2, and/or 
increased LV mass index  




A total of 116 patients were enrolled in the study for a total duration of 6 months. Only 93 patients were 
evaluated at their 6-month follow up due to poor tolerance, side effects, or lack of compliance. The mean patient age 
was 66 with 65% of them being women. Patient comorbidities included 86% with a chronic history of hypertension, 
56% with hyperlipidemia, 20.5% with diabetes, 18.5% with coronary artery disease, and 11.5% with chronic 
obstructive pulmonary disease. The average BMI of the patients in the study was 30, with a majority of patients 




The primary end point for the Conraads et al study was the 6-minute walking distance test. Patients 
randomized to the nebivolol treatment group had a walk distance of 420 meters ± 143 at baseline and improved to 
428 meters  ± 141 after 6 months of treatment, but did not reach statistical significance (P = 0.094).  The placebo 
group walk distances also improved, with 412 meters ± 123 at baseline and 446 meters ± 119 after 6 months.  
 
Peak VO2 values for patients in the Nebivolol study group measured 17.02-mL/kg/min ± 4.79 at baseline 
and decreased to 16.32-mL/kg/min ± 3.76 after 6 months. Baseline measurements in the placebo group increased 
from 17.79-mL/kg/min ± 5.96 at baseline to 18.59-mL/kg/min ± 5.64 after 6 months. Peak VO2 levels at baseline, as 
compared to 6 months, were not statistically significant (P = 0.63). See figures 11 and 12 for 6-minute walking 
distance results and peak VO2 measurements, respectively.  
 
Resting systolic blood pressure for patients taking nebivolol decreased from 128 ± 17 at baseline to 122 ± 
18 at 6 months, which did reach statistical significance (P <0.05). Systolic blood pressure measured during peak 
exercise decreased from 176 ± 29 at baseline to 167 ± 31 after 6 months of treatment, which also reached statistical 
significance (P < 0.05). In contrast, patients in the placebo group had no significant decrease in either resting or peak 
systolic blood pressure.  
 
The biomarker NT-proBNP was measured at baseline and at 6 months. The nebivolol treatment group had a 
slight increase in levels, from 147 pg/ml at baseline to 162 pg/mL after 6 months of treatment. Patients in the 
placebo group had a decrease in values, from 126 pg/mL at baseline to 99 pg/mL after 6 months of treatment. These 
measurements did not reach statistical significance (P = 0.878). See figure 13 for NT-proBNP measurements at 
baseline and after 6 months.  
 
The numbers of adverse events affecting the nebivolol and placebo study groups were 20 and 13, 
respectively. This resulted in the withdrawal of nine patients in the nebivolol group as compared to zero patients in 
the placebo group. [4] 
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Figure 11 – Conraads et al (Study 3) – 6-minute 
walking distance  
Figure 7 – Conraads et al (Study 3) – Peak VO2 
Figure 7 – Conraads et al (Study 3) – NT-proBNP 
levels 
Study 3 Critique  
 
 Strengths of this study included double-blinding using computer-generated, 1:1 randomization to ensure 
complete blinding for both participants and researchers. The study participants were also diverse, as enrollment 
stemmed from 12 hospitals in 8 different countries. Minimal differences in baseline characteristics between the 
nebivolol and placebo groups were found, as most participants were female (65%), with a history of hypertension 
and an average BMI of 30.   
 
 While a majority of study participants being female did allow for similar baseline findings, it also means 
that there was an uneven distribution of participants in terms of gender. This may affect the results of the study, but 
should be expected, as heart failure with a preserved ejection fraction is more common among women than men. 
Although random assignment to study and control groups was used, more patients assigned to the nebivolol group 
(16% vs 7% in the placebo group) had a history of COPD, which may have affected the baseline health of those 
particular patients. While it is good that all participants were either classified as having heart failure class II or III, it 
should be noted that the majority of patients (78%) were considered only class II at the start of the study. This may 
suggest that patients were not sick enough to truly benefit from the effects of nebivolol in terms of beta blockade 
and nitric oxide (NO) release. Nitric oxide is a potent vasodilator that is associated with a decrease in afterload, 
which may contribute to the LV remodeling in terms of lowering the pressure at which the LV pumps against. Less 
pressure to pump against may mean less LV hypertrophy, or less cardiac muscle mass in the LV.  
 
 In order to further support findings of this study, an intention-to-treat analysis was performed in order to 
evaluate efficacy endpoints, which allowed for evaluation using the “last observation carried forward” method in 
patients who were initially enrolled, but not assessed at the end of the 6 month period.  
 
This study did have a very low loss to follow-up, with only 1 in the nebivolol group and none in the 
placebo group. However, the nebivolol group did lose a total of 14 participants due to adverse drug side effects and 






 Heart failure with preserved ejection fraction (HFpEF) is a common clinical syndrome in which patients 
have signs and symptoms of heart failure in addition to a normal ejection fraction (> 45%). These patients also have 
evidence of LV diastolic dysfunction, suggested by physical exam and echocardiogram. Also known as diastolic 
heart failure, this condition has a multitude of etiologies, most commonly chronic systemic hypertension, ischemic 
heart disease, and hypertrophic or restrictive cardiomyopathies. HFpEF tends to affect women more than men. This 
finding may be related to females having abnormal presentation of myocardial infarction, leading to undetected 
ischemic heart disease and thus comorbid heart disease that leads to heart failure because it was never treated to 
begin with. It is also more commonly seen in older adults who have chronic systemic hypertension. It is less likely 
to be seen in patients with prior myocardial infarction. HFpEF is often associated with comorbidities including 
coronary heart disease, diabetes mellitus, obesity, sleep apnea, and kidney disease. [1][3][8] 
 
It is important to distinguish asymptomatic diastolic “dysfunction” from “failure.” Evidence of LV 
dysfunction, as seen on echocardiogram, in addition to a normal ejection fraction (>45%), is not sufficient to 
diagnose a patient with heart “failure”, which requires the presence of signs and symptoms such as dyspnea, 
orthopnea, pulmonary congestion, peripheral edema, and jugular venous distension.  
 
In terms of the treatment of heart failure, proven pharmacologic regimens have only been established for 
those patients with a reduced ejection fraction. HFpEF differs significantly in terms of etiology, pathophysiology, 
and heart structure and dysfunction. Unlike systolic failure, in which poor contractility is the main concern, diastolic 
failure involves normal contractile force with poor ability to relax, thus poor diastolic filling. [1][3][8] 
 
Initial treatment of patients with reduced ejection fraction includes loop diuretics such as furosemide, 
which target symptom relief related to volume overload. Angiotensin converting enzyme inhibitors (ACEI), 
angiotensin II receptor blockers (ARBs) and beta-blockers are also used as initial therapy in addition to the loop 
diuretics. Mineralocorticoid receptor antagonists may also be added to the initial regimen.  
 
It is thought that this treatment regimen might also be successful if used for patients with a preserved 
ejection fraction, or patients with diastolic failure. However, in reviewing the current literature pertaining to the 
treatment of patients with preserved ejection fraction, studies suggest otherwise.  
 
In study 1, Edelmann et al, spironolactone was compared to placebo and results suggest an improvement in 
diastolic dysfunction as seen by a decreased in the E/e’ ratio in the spironolactone group with an increase in the 
placebo group. Additionally, results suggest an improvement in neuroendocrine activation, as seen by a decrease in 
NT-proBNP levels from baseline to the end of the trail 12 months later. While endpoint data do suggest improved 
diastolic function, there was no improvement in exercise capacity, no improvement of patient symptoms, and no 
improvement in overall quality of life. [5] 
 
Study 2, Kurrelmeyer et al, which studied the effects of Spironolactone as compared to placebo in the 
treatment of elderly women with HFpEF, produced results that suggest an improvement in diastolic dysfunction, 
suggested by a decrease in the E/’e ratio, as well as an improvement in BNP levels in the spironolactone group. 
Results showed no improvement in exercise capacity and no significant difference in blood pressures or heart rates 
between Spironolactone and placebo groups. [6] 
 
In study 3, Conraads et al, results suggest no improvement in exercise capacity, as suggested by no change 
in the 6-minute walking distances or peak VO2 levels. Resting and peak blood pressure and heart rate did decreased 
more in the Nebivolol group. Quality of life and NT-proBNP levels were unchanged in both groups. This suggests 
that the use of Nebivolol, a beta-1 adrenergic receptor antagonist, is not effective in the improvement of exercise 
capacity and likely inhibits the chronotropic response to exercise. Changes in the peak exercise capacity are thought 
to be related solely to the negative chronotropic effect of nebivolol. It should be noted that patients in this study had 
mild LV diastolic dysfunction, with 78% of participants deemed class II heart failure. These patients had only mild 
exercise limitations, which mean their baseline was not diminished enough to really show any benefit from the 
administration of a beta-blocker during exercise. [4] 
 
See figures 14-18 for information regarding overall results of the six-minute walking distance, serum BNP 
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Figure 14 – comparison of six-minute walking distances between studies 1, 2, and 3 as 
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Figure	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Figure 15 – Comparison of serum BNP levels between studies 1, 2, and 3 as measured at 
baseline and after full duration of studies.  
Figure 16 – Comparison of peak VO2 levels between studies 1 and 3 as measured at baseline 
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Figure 17 – Comparison of the E/e’ velocity ratios between studies 1 and 2 as measured at 
baseline and after full duration of studies.  
Figure 18 – Comparison of E/A velocity ratios between studies 1 and 2 as measured at baseline 
and after full duration of studies.  
Conclusion  
 
 While there is an established, proven treatment regimen for the management of heart failure in patients with 
a reduced ejection fraction, successful treatment regimens for patients with preserved ejection fraction have not yet 
been proven. Among heart failure patients, nearly half of all diagnosed cases are in patients with diastolic failure, 
which is why there is such a high demand for further research and proven methods of treating this type of failure. 
[1][3][8] 
 
 In reviewing the literature, Nebivolol, a cardio-selective beta-1 adrenergic receptor antagonist, had no 
favorable effect on exercise capacity and was not reported to improve diastolic function. Nebivolol did lower heart 
rate and blood pressure as compared to patients in the placebo group. Spironolactone, a mineralocorticoid receptor 
antagonist, was shown to improve diastolic function, but had no favorable effect on exercise capacity. [4][5][6] 
 
 In addition to primary endpoints of increase in six-minute walking distance and improvement of diastolic 
function, study 2, which considered treatment of elderly women with HFpEF, it was found that after 6 months of 
Spironolactone use, there was a significant decrease in the levels of PIIINP, which is a N-terminal propeptide of 
type III procollagen. Elevations of this biomarker are associated with increased levels of the type III collagen and 
thus fibrotic changes, leading to increased ventricular stiffness. [4][5][6] 
 
 With no proven treatment regimen in the management of HFpEF, it is widely accepted that prevention of 
disease development and progression is the best course of action. Treatment is targeted at management of 
comorbidities and contributing factors, with tight blood pressure control as a main focus. The use of diuretics for 
symptom management and encouraging exercise to promote weight loss and cardiovascular health are also helpful in 
preventing disease development. Weight loss, glycemic control, management of diabetes, and management of 
atherosclerotic coronary artery disease are also key in prevention of disease progression. [8] 
 
 In prescribing mineralocorticoid receptor antagonists (MRA’s) such as Spironolactone, it is important to 
routinely check electrolyte levels and monitor renal function, as this medication can result in hyperkalemia, which 
may manifest as deadly arrhythmias. Additionally, the use of MRA’s with concomitant ACE inhibitor use should be 
done so with caution, as both may contribute to high serum potassium levels, especially in combination. [5][6][8] 
 
 Further research is needed to devise proven methods for treating heart failure in patients with preserved 
ejection fraction and diastolic dysfunction. Current research is lacking in both duration of study and endpoints 
including mortality. This literature review includes articles following participants for only 6 to 12 months in 
duration and does not include statistics concerning rates of mortality associated with use of MRA’s and beta-
blockers. 
 
Further studies need to be performed that include clinical end points of morbidity and mortality. In addition 
the monitoring and treatment of surrogate endpoints such as hypertension and obesity should also play a major role 
in the data that is collected in further studies. The spironolactone studies may also benefit from a study that is longer 
than 6-12 months to further evaluate the effect on diastolic function and ultimately improving symptoms and clinical 
end points of patient with heart failure with preserved ejection fraction. 
 
Clinical Recommendations  
 
 In terms of managing patients in heart failure with a preserved ejection fraction, treatment modalities that 
exist for systolic failure are typically not accepted as being successful in those with diastolic failure. Results of 
clinical trials, including the studies in this literature review, suggest that neurohormonal antagonists such as beta-
blockers, angiotensin converting enzyme inhibitors, and angiotensin II receptor blockers do not decrease the 
morbidity and mortality of patients in diastolic failure.  
 
 At this point, based on results from this literature review and on recommendations made by UpToDate and 
the American Heart Association, we suggest using pharmacologic treatment with diuretics to target symptom 
management. We also suggest focusing on lifestyle changes such as diet modification, smoking cessation, and 
weight loss with structured exercise plans in order to prevent progression of diastolic dysfunction to HFpEF, which 
lacks specific treatment regimens. [1] 
 
 In addition to lifestyle modifications, tight blood pressure control is warranted, as is the treatment of all 
lung disease, coronary artery disease, atrial fibrillation, diabetes mellitus, sleep apnea, and renal disease. These 
comorbid conditions, which are commonly associated with those in HFpEF, should be controlled, as they have 
significant impact on clinical outcomes.  
 
 Currently, UpToDate, which is a well trusted academic resource that many providers use to research 
evidence-based data to help them with decisions in point of care, recommends the use of mineralocorticoid receptor 




 We would like to give a special thanks to Dr. Erika Kancler, who has worked patiently with each of us 
throughout the entire semester, both in and outside of the classroom. We would also like to thank Mrs. Carolyn 
Schubert for the time she spent helping us research our topic and for all of the recommendations she made 
throughout the semester. Thank you so much to the JMU writing center, who spent numerous hours reading and 
editing our work. Thank you to the JMU communications center for their help with poster layouts and presentations. 






























































1. Borlaug BA, Colucci WS. Pathophysiology of heart failure with preserved ejection fraction. UpToDate. 
https://www.uptodate.com/contents/pathophysiology-of-heart-failure-with-preserved-ejection-
fraction?source=search_result&search=diastolic%20heart%20failure&selectedTitle=2~150. Published 
November 9, 2016. Accessed November 20, 2016. 
 
2. Classes of Heart Failure. American Heart Association 
http://www.heart.org/HEARTORG/Conditions/HeartFailure/AboutHeartFailure/Classes-of-Heart-
Failure_UCM_306328_Article.jsp#.WD3nfHd-Icg. Published September 28, 2016. Accessed November 
25, 2016. 
 
3. Colucci WS. Overview of heart failure with reduced ejection fraction. UpToDate. 
https://www.uptodate.com/contents/overview-of-the-therapy-of-heart-failure-with-reduced-ejection-
fraction?source=search_result&search=systolic heart failure&selectedTitle=1~150. Published February 16, 
2016. Accessed November 20, 2016. 
 
4. Conraads VM. Effects of the long-term administration of Nebivolol on the clinical symptoms, exercise 
capacity, and left ventricular function of patients with diastolic dysfunction: results of the ELANDD study. 
European Society of Cardiology. 2011;14:219-225. doi:10.1093/eurjhf/hfr161. 
 
5. Edelmann F, Wachter R. Effect of Spironolactone on Diastolic Function and Exercise Capacity in Patients 
with Heart Failure with Preserved Ejection Fraction . Journal of the American Medical Association 
(JAMA). 2013;309(8):781-791. doi:10.1001/jama.2013.905. 
 
6. Kurrelmeyer KM. Effects of Spironolactone Treatment in Elderly Women with Heart Failure and Preserved 
Left Ventricular Ejection Fraction . Journal of Cardiac Failure. 2014; 20(8):560-567. 
doi:10.1016/j.cardfail.2014.05.010. 
 
7. Muller K. Mitral Inflow signal to assess diastolic dysfunction. 123 Sonography. 
https://123sonography.com/ebook/assess-diastolic-function. Accessed November 23, 2016. 
 
8. Rash B. Acute and Chronic Congestive Heart Failure. November 2016. 
 
 
 
